Clinical Trial Update: Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF [Phase 2]

View source ↗

Summary

Phase II clinical trial update for INC424 (sonidegib) in various myelofibrosis subtypes has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• INC424 (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF | Phase 2 | Status: COMPLETED | Results posted: 2019-09-03